News

OncoGenex has received funding for a randomized, controlled, investigator-sponsored phase 2 clinical trial evaluating OGX-427, when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC).

Aetna acknowledge SpectraCell’s micronutrient testing as a valuable piece of the healthcare puzzle, changing the current paradigm of disease-care to true wellness-care and prevention. SpectraCell’s micronutrient testing provides

Ensemble Discovery has announced the initiation of a strategic alliance with Pfizer, to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical

The diagnostic kits provide a fast, robust, reliable and simple procedure for isolating high quality DNA, RNA, and microRNA suitable for molecular biology applications. The sensitivity and speed

Eisai has completed its acquisition of AkaRx for approximately $255m. As a result of the acquisition, AkaRx is now a wholly-owned subsidiary of Eisai and Eisai has the

Lanxess has acquired the Nipacide PTAP product line from Clariant effective January 1, 2010. The active ingredient, p-tert-amylphenol (PTAP) complements the phenolic active ingredients portfolio of Lanxess’ Material

OncoMed and Fluidigm have formed a strategic collaboration for a new initiative to apply Fluidigm’s microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.

The US Patent and Trademark Office (USPTO) has issued US Patent No 7638485 titled ‘Modulating Apoptosis’ covering the method of protecting a mammal from radiation using flagellin or

Alnylam Pharmaceuticals has received a milestone payment from its partner Roche, related to initiation of pre-IND (investigational new drug application) studies for an RNAi therapeutics product candidate. Financial